Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6ZPR

Solution structure of MLKL executioner domain in complex with a covalent inhibitor

Summary for 6ZPR
Entry DOI10.2210/pdb6zpr/pdb
Related6ZLE
NMR InformationBMRB: 34528
DescriptorMixed lineage kinase domain-like protein,Mixed lineage kinase domain-like protein, 7-(2-methoxyethoxymethyl)-1,3-dimethyl-purine-2,6-dione (2 entities in total)
Functional Keywordsnecroptosis, lipid binding protein
Biological sourceHomo sapiens (Human)
More
Total number of polymer chains1
Total formula weight18453.23
Authors
Ruebbelke, M.,Bauer, M.,Hamilton, J.,Binder, F.,Nar, H.,Zeeb, M. (deposition date: 2020-07-09, release date: 2020-12-16, Last modification date: 2024-11-13)
Primary citationRubbelke, M.,Fiegen, D.,Bauer, M.,Binder, F.,Hamilton, J.,King, J.,Thamm, S.,Nar, H.,Zeeb, M.
Locking mixed-lineage kinase domain-like protein in its auto-inhibited state prevents necroptosis.
Proc.Natl.Acad.Sci.USA, 117:33272-33281, 2020
Cited by
PubMed Abstract: As an alternative pathway of controlled cell death, necroptosis can be triggered by tumor necrosis factor via the kinases RIPK1/RIPK3 and the effector protein mixed-lineage kinase domain-like protein (MLKL). Upon activation, MLKL oligomerizes and integrates into the plasma membrane via its executioner domain. Here, we present the X-ray and NMR costructures of the human MLKL executioner domain covalently bound via Cys86 to a xanthine class inhibitor. The structures reveal that the compound stabilizes the interaction between the auto-inhibitory brace helix α6 and the four-helix bundle by stacking to Phe148. An NMR-based functional assay observing the conformation of this helix showed that the F148A mutant is unresponsive to the compound, providing further evidence for the importance of this interaction. Real-time and diffusion NMR studies demonstrate that xanthine derivatives inhibit MLKL oligomerization. Finally, we show that the other well-known MLKL inhibitor Necrosulfonamide, which also covalently modifies Cys86, must employ a different mode of action.
PubMed: 33318170
DOI: 10.1073/pnas.2017406117
PDB entries with the same primary citation
Experimental method
SOLUTION NMR
Structure validation

237992

数据于2025-06-25公开中

PDB statisticsPDBj update infoContact PDBjnumon